Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02211196 · ClinicalTrials.gov registry record · NA

Evidence-Based Tobacco Cessation Strategies in Patients With Cancer

A NA study of Malignant Neoplasm, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
NA
Development phase
377
Enrollment target
1
Study location

NCT02211196: Completed NA study of Malignant Neoplasm, sponsored by Wake Forest University Health Sciences.

NCT02211196 is a NA study of Malignant Neoplasm that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 377 participants, below the 507-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02211196, a NA study of Malignant Neoplasm, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
NA
Development phase
377 participants
Enrollment target
1
Study location

Study Summary

This pilot clinical trial studies evidence-based tobacco cessation strategies in patients with cancer. Stop-smoking plans suggested by doctors may help patients with cancer quit smoking.

Primary Outcome

Will be estimated and 95% confidence intervals (CI) constructed.

Conditions Studied

Interventions

  • OTHER questionnaire administration
  • OTHER survey administration
  • BEHAVIORAL smoking cessation intervention

Study Locations (1)

North Carolina

  • Comprehensive Cancer Center of Wake Forest University - Winston-Salem

Trial Details

FieldValue
Enrollment Target 377 participants
Start Date 2013-02
Est. Completion 2014-11
Phase NA
Wake Forest University Health Sciences

1,140 total trials

What the finished NCT02211196 record still lists

NCT02211196 is an interventional study that assigns participants to a tested intervention. The registered 377 participants enrollment target is mid-sized for trials with a published cap, below the 507-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (26% lower).

The record links to 1 condition, with Malignant Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which questionnaire administration is the first listed.

NCT02211196 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT02211196 about?

NCT02211196 is a clinical study titled "Evidence-Based Tobacco Cessation Strategies in Patients With Cancer". This pilot clinical trial studies evidence-based tobacco cessation strategies in patients with cancer. Stop-smoking plans suggested by doctors may help patients with cancer quit smoking.

What is the current status of trial NCT02211196?

This trial is currently completed. It is a NA study. The enrollment target is 377 participants. The study started on 2013-02. Estimated completion is 2014-11.

What conditions does trial NCT02211196 study?

This clinical trial studies the following conditions: Malignant Neoplasm.

What interventions are being tested in trial NCT02211196?

The interventions under investigation include: questionnaire administration (OTHER), survey administration (OTHER), smoking cessation intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT02211196?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02211196 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02211196's enrollment target sits among peer trials

377 14th of 59 higher than 46 of 59 other Malignant Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07024784 · 377 participants · Phase 2

    A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

  • NCT04254185 · 378 participants · NA

    Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow

  • NCT06616584 · 378 participants · Phase 2

    Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • NCT03102125 · 376 participants · Phase 4

    Allograft Dysfunction in Heart Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02211196, the US trial registry maintained by the National Library of Medicine. NCT02211196 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.